Full Text

Turn on search term navigation

© 2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Study objectives

To compare the prices paid for nicotine vaping products (NVPs) and supplies among current NVP users to prices paid for cigarettes among current smokers.

Data

The 2016 International Tobacco Control Four Country Vaping and Smoking Survey (4CV1). Key measures included: (1) self-reported prices paid for reusable NVPs (eg, rechargeable devices with cartridges and tank system devices with e-liquids) in the 3-month period prior to the survey among current NVP users, (2) prices paid for disposable NVPs, cartridges and e-liquids purchased in the last 30 days among current NVP users and (3) self-reported prices paid for cigarettes among current smokers.

Results

Disposable NVP price was higher than the price of a comparable unit for combustible cigarettes in England (EN), USA and Canada (CA). Prefilled cartridge price was higher than the price of a comparable unit of cigarettes in USA and CA, but lower in EN and Australia. E-liquid price was consistently lower than the price of a comparable unit of cigarettes across four countries. For start-up costs, price of a rechargeable device is approximately 3–5 times higher than a pack of cigarettes in four countries.

Conclusion

NVP prices were generally higher than prices of combustible cigarettes, especially the high upfront NVP devices. The high upfront costs of purchasing a reusable NVP may discourage some smokers from switching to vaping. However, the average lower costs of cartridges and e-liquids relative to a package of cigarettes make switching to a NVP an attractive alternative to smoking in the long term so long as smokers switch completely to vaping.

Details

Title
Costs of vaping: evidence from ITC Four Country Smoking and Vaping Survey
Author
Kai-Wen, Cheng 1   VIAFID ORCID Logo  ; Shang, Ce 2 ; Hye Myung Lee 3 ; Chaloupka, Frank J 3 ; Fong, Geoffrey T 4   VIAFID ORCID Logo  ; Borland, Ron 5   VIAFID ORCID Logo  ; Heckman, Bryan W 6   VIAFID ORCID Logo  ; Hitchman, Sara C 7   VIAFID ORCID Logo  ; O'Connor, Richard J 8 ; Levy, David T 9   VIAFID ORCID Logo  ; Cummings, K Michael 6   VIAFID ORCID Logo 

 Department of Health Administration, Governors State University, University Park, Illinois, USA; Health Policy Center, Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, Illinois, USA 
 Department of Pediatrics and Oklahoma Tobacco Research Center, University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, USA 
 Health Policy Center, Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, Illinois, USA 
 Department of Psychology and School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada 
 School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia; Cancer Council Victoria, Melbourne, Victoria, Australia 
 Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, US 
 Department of Addictions, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK 
 Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, New York, USA 
 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA 
Pages
94-97
Section
Original research
Publication year
2021
Publication date
Jan 2021
Publisher
BMJ Publishing Group LTD
ISSN
09644563
e-ISSN
14683318
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2470158968
Copyright
© 2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.